The deal was publicly announced on the Chinese Stock Exchange the same day, and will leverage the capabilities and experience in interventional cardiology of its subsidiary, Biosensors International Group.

China based Blue Sail Medical recently announced that the company made a purchase offer to acquire all shares of  New Valve Technology (NVT) AG, Muri (Argau, Switzerland), and that the offer was accepted by the shareholders of NVT.

The shareholders of NVT and Blue Sail Medical are pleased to announce that Blue Sail Medical and the shareholders of NVT signed a Sales and Purchase Agreement relating to all shares in NVT.

"The main business of NVT is in R&D, production and sales of structural heart disease interventional valve products. We are excited about this acquisition because, as the population ages, the incidence of vascular heart disease gradually increases," commented Mr Simon Li, CEO of Blue Sail Medical Co., Ltd. & Biosensors International Group.

This will help NVT to gain share in the TAVI market. We believe Biosensors will drive the growth of our existing business, expand into new geographies such as China, a market with enormous growth potential, and also help accelerate our R&D initiatives."

Urs Christen, President and CEO of NVT commented, "Biosensors is strategically positioned to accelerate the adoption of our products through its highly complementary and global direct sales force focused on interventional cardiology.

-----------------------------------------------------------------------
Editor's Note: For any copyright disputes involving the content,
please email: Julia.Zhang@ubmsinoexpo.com to delete.